2014
DOI: 10.1007/978-3-319-07887-8_5
|View full text |Cite
|
Sign up to set email alerts
|

Will New Technologies Replace Mammography CAD as We Know It?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2015
2015
2015
2015

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…A newly developed 2D imaging “modality” called C-View (synthetic 2D view) can be generated from the 3D DBT data during the mammography exam [ 111 ], eliminating the need for additional 2D exposures. Initial clinical studies have shown that screening with C-View imaging may result in clinical performance superior to that of a conventional 2D mammogram [ 112 ]. However, further evaluation and validation are needed to verify the usage of C-View in a clinical environment.…”
Section: Screen Mammographymentioning
confidence: 99%
“…A newly developed 2D imaging “modality” called C-View (synthetic 2D view) can be generated from the 3D DBT data during the mammography exam [ 111 ], eliminating the need for additional 2D exposures. Initial clinical studies have shown that screening with C-View imaging may result in clinical performance superior to that of a conventional 2D mammogram [ 112 ]. However, further evaluation and validation are needed to verify the usage of C-View in a clinical environment.…”
Section: Screen Mammographymentioning
confidence: 99%
“…The C-View TM image is created directly from the 3D data set. 3 Despite these benefits, one potential hurdle for DBT is calcification imaging. Multiple studies have suggested that calcification clusters are not as clearly visible in DBT.…”
Section: Introductionmentioning
confidence: 99%
“…This paper evaluates the potential merits of this prototype CAD algorithm (Hologic ® ImageChecker ® 3D Calc CAD v1.0). 3 Unlike the conventional 2D CAD algorithm for DM (Hologic ® ImageChecker ® CAD v9.4), the 3D CAD algorithm is not yet approved by the United States Food and Drug Administration (FDA), and is intended for investigational use in the United States. Drawing from Penn's database of screening exams, the cases considered in this project span a broad range of features, including:…”
Section: Introductionmentioning
confidence: 99%